CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease

Neurology

Volumn 78, Issue 10, 2012, Pages 709-719

  Tarawneh, R ^a   Lee, J M ^a   Ladenson, J H ^a   Morris, J C ^a   Holtzman, D M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEURONAL CALCIUM SENSOR; TAU PHOSPHORYLATED AT THREONINE 181; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN 1;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; STATISTICAL MODEL;

EID: 84860832253     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318248e568     Document Type: Article

References (39)

1. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368. (Pubitemid 29120041)
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
3. Price JL, Ko AI, Wade MJ, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58:1395-1402. (Pubitemid 32845990)
4. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005;65: 1227-1231. (Pubitemid 41508215)
5. Braunewell K, Riederer P, Spilker C, et al. Abnormal localization of two neuronal calcium sensor proteins, visininlike proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord 2001;12:110-116. (Pubitemid 32149716)
6. Laterza OF, Modur VR, Crimmins DL, et al. Identification of novel brain biomarkers. Clin Chem 2006;52: 1713-1721. (Pubitemid 44330705)
7. Lee JM, Blennow K, Andreasen N, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer's disease patients. Clin Chem 2008;54:1617-1623.
8. Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011;70:274-285.
9. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994;343: 1432-1433. (Pubitemid 24167530)
10. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43: 2412-2414. (Pubitemid 23346995)
11. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006;67:467-473. (Pubitemid 44214972)
12. Berg L, Miller JP, Baty J, et al. Mild senile dementia of the Alzheimer type: 4: Evaluation of intervention. Ann Neurol 1992;31:242-249.
13. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335. (Pubitemid 28146197)
14. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-216. (Pubitemid 44900933)
15. Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988;38:900-903.
16. Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York: Psychological Corporation; 1973.
17. Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1955.
18. Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders, 2nd ed. Philadelphia: Lea & Febiger; 1983.
19. Thurstone LL, Thurstone LG. Examiner Manual for the SRA Primary Mental Abilities Test. Chicago: Chicago Science Research Associates; 1949.
20. Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psychol Monographs 1946;60:1-48.
21. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66:1254-1259.
22. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59: 512-519. (Pubitemid 43358072)
23. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaqueassociated changes in amyloid-beta metabolism and halflife. J Neurosci 2003;23:8844-8853. (Pubitemid 37210896)
24. Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: A link between calcium sensors and Alzheimer's disease? Neurobiol Dis 2001;8:900-909. (Pubitemid 33055604)
25. Ito K, Corrigan B, Zhao Q, et al. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement 2011;7:151-160.
26. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009;66:638-645.
27. Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009;73:1353-1358.
28. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925-931. (Pubitemid 38435780)
29. Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: Development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009;8: 144-159.
30. Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007;419:18-22. (Pubitemid 46694097)
31. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56: 673-680. (Pubitemid 29266465)
32. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 2009;73:294-301.
33. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64:1294-1297.
34. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006;5:228-234. (Pubitemid 43238346)
35. Dudas RB, Clague F, Thompson SA, et al. Episodic and semantic memory in mild cognitive impairment. Neuropsychologia 2005;43:1266-1276. (Pubitemid 40798357)
36. De Jager CA, Hogervorst E, Combrinck M, Budge MM. Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease. Psychol Med 2003;33:1039-1050. (Pubitemid 37009822)
37. Aggleton JP, Brown MW. Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci 1999;22:425-444; discussion 444-489. (Pubitemid 29381683)
38. Martin A, Chao LL. Semantic memory and the brain: Structure and processes. Curr Opin Neurobiol 2001;11: 194-201. (Pubitemid 32289406)
39. Convit A, de Asis J, de Leon MJ, et al. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging 2000;21:19-26. (Pubitemid 30224781)